Literature DB >> 17187361

EMP3 overexpression is associated with oligodendroglial tumors retaining chromosome arms 1p and 19q.

Kay Ka Wai Li1, Jesse Chung-Sean Pang, Nellie Yuk-Fei Chung, Yeung Lam Ng, Norman Hok Ling Chan, Liangfu Zhou, Wai Sang Poon, Ho-Keung Ng.   

Abstract

The epithelial membrane protein 3 (EMP3) gene located on chromosome 19q13 has been implicated as a candidate tumor suppressor gene (TSG) in neuroblastomas and gliomas. The aim of this study was to investigate whether EMP3 is involved in oligodendroglial tumors (OTs), which frequently carry combined chromosomes 1p and 19q deletion. We first investigated the transcript level of EMP3 in a cohort of 57 OTs by quantitative real-time RT-PCR. Our results showed that 10 (18%) tumors had reduced EMP3 expression level compared to normal brains. Six of these tumors carried chromosome 19q13 deletion but no statistical correlation was found between the 2 parameters. Intriguingly, a similar proportion (11 of 57, 19%) of tumors displayed EMP3 overexpression, with 8 of them having transcript level >10-fold higher than normal brain. All 11 OTs retained chromosomes 1p36 and 19q13, and a significant association was found between EMP3 overexpression and balanced chromosomes 1p36 and 19q13 (p = 0.004). The methylation status of EMP3 was evaluated by bisulfite sequencing in 29 OTs with diverse expression levels. All tumors except 3 showed aberrant methylation of EMP3 and no correlation was observed between transcript level and methylation status, suggesting that methylation alone does not mediate transcriptional down-regulation of EMP3 in OTs. In conclusion, our study demonstrates that EMP3 overexpression is involved in OTs retaining chromosomes 1p and 19q and does not support EMP3 as the target TSG on chromosome 19q13 in OTs.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17187361     DOI: 10.1002/ijc.22415

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  7 in total

Review 1.  Review of the GAS3 Family of Proteins and their Relevance to Cancer.

Authors:  Negin Ashki; Lynn Gordon; Madhuri Wadehra
Journal:  Crit Rev Oncog       Date:  2015

2.  Gene expression profile analysis of primary glioblastomas and non-neoplastic brain tissue: identification of potential target genes by oligonucleotide microarray and real-time quantitative PCR.

Authors:  Carlos A Scrideli; Carlos G Carlotti; Oswaldo K Okamoto; Vanessa S Andrade; Maria A A Cortez; Fábio J N Motta; Agda K Lucio-Eterovic; Luciano Neder; Sérgio Rosemberg; Sueli M Oba-Shinjo; Suely K N Marie; Luíz G Tone
Journal:  J Neurooncol       Date:  2008-04-09       Impact factor: 4.130

3.  Epithelial membrane protein 3 functions as an oncogene and is regulated by microRNA-765 in primary breast carcinoma.

Authors:  Xiao Chun Hong; Yuan Jian Fen; Guo Chun Yan; Hong Hong; Cao Hong Yan; Li Wei Bing; Yu Hai Zhong
Journal:  Mol Med Rep       Date:  2015-09-14       Impact factor: 2.952

4.  Targeting EMP3 suppresses proliferation and invasion of hepatocellular carcinoma cells through inactivation of PI3K/Akt pathway.

Authors:  Yi-Hsien Hsieh; Shu-Ching Hsieh; Chien-Hsing Lee; Shun-Fa Yang; Chun-Wen Cheng; Meng-Ju Tang; Chia-Liang Lin; Chu-Liang Lin; Ruey-Hwang Chou
Journal:  Oncotarget       Date:  2015-10-27

5.  Promoter hypermethylation of the EMP3 gene in a series of 229 human gliomas.

Authors:  Marta Mellai; Angela Piazzi; Valentina Caldera; Laura Annovazzi; Oriana Monzeglio; Rebecca Senetta; Paola Cassoni; Davide Schiffer
Journal:  Biomed Res Int       Date:  2013-09-03       Impact factor: 3.411

6.  EMP3 overexpression in primary breast carcinomas is not associated with epigenetic aberrations.

Authors:  Wei Zhou; Zheng Jiang; Xingang Li; Fenghua Xu; Yanbing Liu; Peie Wen; Li Kong; Ming Hou; Jinming Yu
Journal:  J Korean Med Sci       Date:  2009-02-28       Impact factor: 2.153

7.  Epithelial membrane protein 3 regulates TGF-β signaling activation in CD44-high glioblastoma.

Authors:  Fu Jun; Jidong Hong; Qin Liu; Yong Guo; Yiwei Liao; Jianghai Huang; Sailan Wen; Liangfang Shen
Journal:  Oncotarget       Date:  2017-02-28
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.